CAR-T Cell Therapy Market

CAR-T Cell Therapy Market Size, Share & Trends Analysis Report

CAR-T Cell Therapy Market Size, Share & Trends Analysis Report By Product Type (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Lisocabtagene Maraleucel, Idecabtagene Vicleucel, Others), By Indication (Acute Lymphocytic Leukemia, Diffuse Large B-cell lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Multiple Myeloma, Others), By End-user (Hospitals, Cancer Treatment Centers), Based On Region And Segment Forecasts 2022 - 2028

Report ID : BMRC 1553
Number of pages : 300
Published Date : Dec 2022
Category : Healthcare
Delivery Timeline : 48 hrs

Global CAR-T Cell Therapy Market: Global Size, Trends, Competitive, And Historical & Forecast Analysis, 2022-2028: Increasing prevalence of cancer across the globe, growing pharmaceutical industry, technological advancements in the treatment therapies for cancer, and increase in the number of clinical studies for cell therapy are some of the major factors driving the growth of the global CAR-T cell therapy market.

Global CAR-T Cell Therapy Market is valued at USD 1.5 Billion in 2021 and is expected to reach USD 10.6 Billion by 2028 with a CAGR of 32.3% over the forecast period.


CAR-T Cell Therapy is nothing but the treatment in which a patient’s T cells-a type of immune system cell are changed in the laboratory for the treatment of cancer. The advantages of CAR T-cell therapies over standard medicines include the use of patient's immune systems to destroy cancer cells, shorter treatment time, and early recovery. Furthermore, CAR T-cell therapy has a long survival time inside the body due to its ability to recognize and aim cancer cells even when cancer reappears. CAR T-cell therapy is primarily employed to treat acute lymphocytic leukemia, lymphoma, and multiple myeloma. CAR T-cell therapy products have a high adoption rate due to their numerous advantages over conventional drugs.

The COVID-19 outbreak is had a negative impact on the CAR T-cell therapy market, as a large number of clinical colleges and hospitals around the world were reorganised to boost hospital capacity for COVID-19 patients. Discovery and development of CAR T-cell therapy medicine slowed down during the pandemic but did not stop. The substantial decrease in drug testing due to strict government guidelines against COVID-19 restrained the market growth. The decline in individual transit, border closures, and population confinement influenced the supply chains of medical products in the CAR T-cell therapeutic market share. Due to the rapidly increasing COVID-19 cases, non-essential surgical techniques took a potential backlog, and home-setting care was favored, as only optional emergency surgeries were performed. As a result, growth in the car-t cells market slowed during the pandemic. However, with the introduction of various COVID-19 vaccinations, people are able to more easily access hospitals and cancer treatment centres, resulting in an increase in demand for CAR T-cell therapy. Post COVID-19 the demand for CAR T-cell therapeutic medicine is expected to rise due to an increase in R&D activities, the recent commercialization of CAR-T cell therapy, and rapidly expanding clinical trial activities. As a result, such progress is expected to bring stability and propel the CAR T-cell therapy market forward.

The global CAR-T Cell Therapy market is segmented based on product type, indication, end-user, and region & country level. Based on product type, the global CAR-T Cell Therapy market is segmented into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, idecabtagene vicleucel, and others. By indication, the market is segmented into acute lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, and others. By end-user, the global CAR-T Cell Therapy market is segmented into Hospitals and Cancer Treatment Centers.

The regions covered in the global CAR-T Cell Therapy market report are North America, Europe, Asia-Pacific, Latin America, and the rest of the World. Based on country level, the market of global CAR-T Cell Therapy is sub divided into U.S., Mexico, Canada, U.K., France, Germany, China, Italy, India, Japan, Southeast Asia, Middle East Asia (Saudi Arabia, UAE, Egypt) GCC, Africa, etc.

Key Players-

Some major key players for the global CAR-T Cell Therapy market report cover prominent players like -

  • Bluebird bio Inc.
  • Autolus Therapeutics
  • Caribou Biosciences Inc.
  • Bristol-Myers Squibb
  • Therapeutics Inc.
  • Cartesian
  • Cellectis
  • Celyad Oncology
  • Celgene Corporation
  • Intellia Therapeutics
  • Gilead Sciences Inc. (Kite Pharma Inc.)
  • Merck & Co. Inc.
  • Juno Therapeutics Inc.
  • Pfizer Inc.
  • Novartis AG
  • Miltenyi Biotech
  • Sorrento Therapeutics Inc.


By Product Type:

  • Axicabtagene Ciloleucel
  • Tisagenlecleucel
  • Brexucabtagene Autoleucel
  • Lisocabtagene Maraleucel
  • Idecabtagene Vicleucel
  • Others

By Indication:

  • Acute Lymphocytic Leukemia
  • Diffuse Large B-cell lymphoma
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Multiple Myeloma
  • Others

By End-user:

  • Hospitals
  • Cancer Treatment Centers

By Regional & Country Level:

  • North America

    • U.S.
    • Canada
  • Europe

    • U.K.
    • France
    • Germany
    • Italy
  • Asia Pacific

    • China
    • Japan
    • India
    • Southeast Asia
  • Latin America

    • Brazil
    • Mexico
  • Middle East and Africa

    • GCC
    • Africa
    • Rest of Middle East and Africa

Increasing prevalence of cancer across the globe, growing pharmaceutical industry, technological advancements in the treatment therapies for cancer, and increase in the number of clinical studies for cell therapy are some of the major factors driving the market growth

The CAR-T therapy market is expected to expand due to the increasing prevalence of cancer cases worldwide. Due to the remarkable results this treatment has produced in patients, it has attracted the interest of both researchers and the general public. In 2017, the FDA approved two CAR T treatments, one for adults with advanced lymphomas and the other for children with acute lymphoblastic leukemia (ALL).

The life science and biotechnology sectors have seen steady growth in the cancer treatment field with chimeric antigen receptors. Rising patient assistance programs (PAPs), increased government cancer awareness programs, rising cancer prevalence globally, and strong Research and development proposals from major manufacturers are all driving the CAR-T cell therapy market. With the increasing demand for cell-based therapy, manufacturers have begun to invest in its production.

Increased prevalence of blood cancer, as well as increased incidences of leukemia and lymphoma, lead to the widespread use of CAR T-cell therapy products, propelling the market growth. According to The Leukemia & Lymphoma Society, approximately 34,920 new cases of myeloma (15,600 females and 19,320 males) are predicted to be diagnosed in the United States in 2021, with an estimated 138,415 people living with or in remission. As per The Leukemia & Lymphoma Society, 61,090 people in the United States are predicted to be diagnosed with leukemia in 2021, and around 397,501 people in the United States are living with or in relapse from leukemia.

Various growth constraints emerge as key issues for the market as it continues to grow during the forecast period. One of the major challenges that market participants face is an absence of treatment demand. The target group is too rigid and only understands native methods of treatment. Furthermore, the associated cost of diagnosis is very high, which does not sit well with individuals since they come from different income levels and have different financial capacities. If prices and costs are not reduced, the CAR-T cell therapy market operations are expected to be significant market restraints.

One of the major world's leading causes of population death is the increasing number of people being diagnosed with different types of cancer. As a result, the need of the hour is for businesses to develop the cytotoxic immunotherapies and conventional that are currently available on a global scale. Tumors are thought to have complex behaviors, and the extent of involvement of a range of cellular and genetic factors in tumorigenesis and metastasis is forcing businesses to divert their developments in the creation of new treatment trends to make the main focus on tumors at both the stated levels.

North America is Expected to Capture a Major Share in the Global CAR-T Cell Therapy Market

Increasing cancer cases and the introduction of the biotechnological industry in North America are expected to make the region the global leader in CAR-T cell therapy. North America is experiencing an increase in cancer cases, which is driving up demand for treating cancer in the region. The presence of key players in the region, such as Bellicum Pharmaceuticals, Inc., Amgen Inc., Caribou Biosciences, Inc., and Bluebird Bio are concentrating on broadening their global presence, which is fueling the CAR-T cell therapy market.

The CAR-T treatment industry is expected to grow quickly as a result of changing market trends in Europe and the increased use of relevant methods. The first medicines supported by the EMA's Priority Medicines (PRIME) scheme, Kymriah, and Yescarta, earned positive views from the Committee for Medicinal Products for Human Use (CHMP), boosting the CAR-T market.

Kymriah is approved to treat refractory or relapsed B-cell ALL in pediatric and young adult patients (up to the age of 25), and also elderly patients with refractory or relapsed DLBCL after two different lines of systemic therapy. Yescarta is indicated for the treatment of elderly patients with refractory or relapsed DLBCL and main mediastinal large B-cell lymphoma after two or more lines of systemic therapy (PMBCL).


The FDA approved Bristol Myers Squibb's CAR T Cell Therapy in the United States. Breyanzi for Refractory or Relapsed Large B-cell Lymphoma After Previous Treatment

On June 2022; Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, was approved by the US Food and Drug Administration (FDA) for adult patients being treated with large B-cell lymphoma (LBCL), which include diffuse large B-cell lymphoma (DLBCL).

Kite begins operations in car t-cell therapy in Singapore, Brazil, and Saudi Arabia

On August 31st, 2022; Kite, a Gilead Corporation, announced the expansion of its operations in Singapore, Brazil, and Saudi Arabia. Kite has filed regulation applications in all three countries for its CAR T-cell therapies. Advanced blood types of cancer portray an area of substantial need across all three countries. Lymphomas are the fifth most common cancer both in Saudi Arabia and Singapore; each year, more than 1,000 cases reported of non-Hodgkin lymphoma (NHL) are diagnosed in Singapore and around 1,700 in Saudi Arabia. And over 12,000 cases of NHL are predicted to be diagnosed in Brazil each year.

Report Analysis Details
Historical data 2018 - 2021
Forecast Period 2022 - 2028
Market Size in 2021: USD 1.5 Billion 
Base year considered 2021
Forecast Period CAGR %:


Market Size Expected in 2028: USD 10.6 Billion
Tables, Charts & Figures: 175
Pages 200
Companies Bluebird bio, Inc., Autolus Therapeutics, Caribou Biosciences, Inc., Bristol-Myers Squibb, Therapeutics, Inc., Cartesian, Cellectis, Celyad Oncology, Celgene Corporation, Intellia Therapeutics, Gilead Sciences, Inc. (Kite Pharma Inc.), Merck & Co., Inc., Juno Therapeutics, Inc., Pfizer, Inc., Novartis AG, Miltenyi Biotech, and Sorrento Therapeutics, Inc. 
Segments Covered By Product Type, By Indication, By End-user
Regional Analysis North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa